U.s. patent office completes review of medtronic patents, rejects more axonics challenges

Dublin, sept. 22, 2021 /prnewswire/ -- medtronic (nyse:mdt), the global leader in medical technology, today announced that the patent trial and appeal board (ptab) of the u.s. patent and trademark office has affirmed an additional three patents in a dispute with axonics over intellectual property for its sacral neuromodulation (snm) device family, the interstim™ systems.
MDT Ratings Summary
MDT Quant Ranking